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Abstract
Ovarian stimulation is an important step in the success rate of in vitro fertilization (IVF) allowing multiple follicular growth, several oocytes
and consequently more embryos. The combination of GnRH-antagonists (GnRH-ant) and gonadotrophins is now available for clinical use and
represent a valid alternative to classical protocol with GnRH agonist. GnRH-antagonists induce a direct block of GnRH receptor with a rapid
decrease in LH and FSH, preventing LH surge. Two protocols has been designed for assisted reproduction technology (ART) treatment:
multiple-dose protocol and a single-dose. Both protocols are simply, efficacious, started in the late follicular phase and do not have side
effects. A review of GnRH-antagonist applications in ART cycles are presented. Smaller doses of gonadotrophins, shorter stimulation period
and lower ovarian hyperstimulation syndrome (OHSS) incidence are reported in literature using GnRH-antagonist compared to agonist.
Triggering of ovulation, the use in polycystic ovarian syndrome (PCOS) and poor reponders patients are other interesting indication.
Regarding to pregnancy rate and potentially adverse effects of drugs on endometrium or implantation needed more data.
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1. Introduction
The in vitro fertilization (IVF) process involves controlled
ovarian stimulation (COS) to stimulate follicular growth.
Gonadotrophin preparations, such as human menopausal
gonadotrophin (hMG) or recombinant human follicle sti-
mulating hormone (rhFSH), are usually used to stimulate the
ovaries to produce oocytes. Human chorionic gonadotrophin
(hCG) is then used to induce oocyte maturation and to
trigger ovulation in stimulated cycles if appropriate.
Cancellation (i.e. not proceeding with treatment in that
cycle) may be advised because of a poor response or
excessive response to ovarian stimulation. In gonadotrophin
treated cycles a premature luteinizing hormone (LH) surge
and premature ovulation may require cancellation.
In fact, high LH levels have a negative role in IVF, so
reduction in bioactive LH levels in the serum is desirable,
particularly in the light of evidence associating raised LH
levels in the follicular phase with adverse reproductive
outcomes [1]:
 Reduced fertilization and pregnancy rates.
 Increased spontaneous abortion rate.
Most specialist infertility clinics attempt to minimise
premature LH surges using pituitary down-regulation.
To achieve this, gonadotrophin-releasing hormone ago-
nists (GnRH-a) were introduced into IVF superovula-
tion regimens in the late 1980s and have become
established as a component of standard regimens in
most centres worldwide.
The inclusion of GnRH-a in ovarian stimulation protocols
for assisted reproduction technologies (ART) has resulted in
significant improvements in outcome [2]:
 Cycle cancellation rates have decreased.
 Clinical pregnancy rates have increased.
In fact, before GnRH-a became available, approximately
20% of stimulated cycles within an IVF program were
cancelled due to premature LH surges. By using the
GnRH-a to prevent LH surges via gonadotrope GnRH
receptor (GnRH-R) down-regulation and desensitisation,
this percentage decreased to about 2%, and concomi-
tantly, the IVF and pregnancy rates (PR) per cycle
initiated were increased.
Several treatment schedules currently are in use (long,
short, or ultrashort protocol): the long protocol, in which the
GnRH-a is begun in the luteal phase of the cycle preceding
the treatment (stimulation) cycle and down-regulation
occurs before the start of the gonadotrophin-stimulation
treatment phase, is generally the most effective regimen
and is presently the most frequently used protocol. However,
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it has some disadvantages, such as hypoestrogenic side
effects and an increase in the number of ampoules of
FSH or hMG required for adequate stimulation [3].
Low doses of the native peptide delivered in a pulsatile
manner to mimic that found in the hypothalamic portal
vessels restore fertility in hypogonadal patients, and are
also effective in treating cryptorchidism and delayed pub-
erty. Administration of high doses of GnRH or agonist
analogues causes desensitisation of the gonadotrope gland
with consequent decline in gonadal gametogenesis and
steroid and peptide hormone synthesis. This phenomenon
finds extensive therapeutic application in clinical medicine
in a wide spectrum of diseases and in IVF to avoid LH
incraese. In addition, GnRH analogues could be used as new
generation male and female contraceptives in conjunction
with steroid hormone replacement.
GnRH-antagonists (GnRH-ant) inhibit the reproductive
system through competition with endogenous GnRH for the
receptor and, in view of their rapid effects, are being
increasingly used for the above mentioned applications.
2. Pharmacology
GnRH is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly.NH2) characterized in 1971 by Schally et al.
[4] which is produced from a precursor polypeptide in
hypothalamic neurons and secreted in a pulsatile manner
to stimulate the secretion of LH and FSH via its interaction
with the receptor on gonadotropes.
GnRH amino acids with crucial functions are at positions 1,
2, 3, 6, and 10. Position 6 is involved in enzymatic cleavage,
positions 2 and 3 in gonadotrophin release, and positions 1, 6,
and 10 are important for the three-dimensional structure.
Synthetic analogues of GnRH with a deletion or substitu-
tion of the histidine in position 2 have been shown to be
competitive antagonists of the native hormone by means of
their ability to bind to, but not activate, the GnRH-R. Further
substitutions at positions 1, 3, 6, 8, and 10 in the molecule
have resulted in progressive increases in antagonistic
potency and improved physical–chemical characteris-
tics.Thus, the structures of the antagonists, unlike the ago-
nists, which only differ for one amino acid (residue 6),
substantially differ from that of GnRH. Five of the 10 amino
acids are unnatural and of D configuration (Fig. 1).
The first generation of GnRH-ant had the disadvantage of
producing adverse side effects which were constituted above
all by anaphylactic reactions due to histamine release. The
structural combination of a hydrophobic N-terminus (resi-
dues 1–3) and a basic/hydrophilic C-terminus (residues 6
and 8) was thought to be responsible for some of these
reactions encountered also, even if to a lesser extent, with the
second generation of GnRH-ant. This side effect was greatly
reduced in the third generation by substituting the appro-
priate combination of amino acids at positions 5, 6, and 8
(Fig. 2).
To the third generation of GnRH-ant belong cetrorelix and
ganirelix, which competitively inhibit the secretion of LH
and FSH from the pituitary gland and oestradiol (E2), by
blocking the binding of GnRH to pituitary GnRH-R with a
dose-dependent mechanism that is maintained throughout
continuous treatment and is reversible after treatment dis-
continuation [5–9]. In IVF the minimal effective doses of
these drugs to prevent LH surges are 0.25 mg per day for
the multiple-dose protocol and 3 mg for the single-dose
protocol, administered via the subcutaneous (SC) route.
Cetrorelix has a low histamine-releasing potential.
In infertile women treated with cetrorelix pituitary
Agonists
1 2 3 4 5 6 7 8 9 10
GnRH pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2
Buserelin 1 2 3 4 5 D-Ser 7 8 9ethylamide
Goserelin 1 2 3 4 5 D-Ser 7 8 9 AzGly
Leuprolin 1 2 3 4 5 D-Leu 7 8 9ethylamide
Triptorelin 1 2 3 4 5 D-Trp 7 8 9 Gly-NH2
Nafarelin 1 2 3 4 5 D-Nal 7 8 9 Gly-NH2
Cetrorelix D-Nal D-Phe D-Pal 4 5 D-Cit 7 8 9 D-Ala
Nal-Glu D-Nal D-Phe D-Pal 4 Arg D-Glu 7 8 9 D-Ala
Antide D-Nal D-Phe D-Pal 4 NicLys D-Niclys 7 Lys(iPr) 9 D-Ala
Ganirelix D-Nal D-Phe D-Pal 4 5 D-hArg 7 hArg 9 D-Ala
AzalineB D-Nal D-Phe D-Pal 4 Phe D-Phe 7 Lys(iPr) 9 D-Ala
Degarelix D-Nal D-Cpa D-Pal 4 Aph D-Aph 7 Lys(iPr) 9 D-Ala
Antagonists
Fig. 1. Amino-acid sequences of GnRH analogues.
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Fig. 2. GnRH antagonist evolution.
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responsiveness was preserved [10]. During GnRH-ant
administration, an escalating dose regimen of LH replace-
ment is optimal for maintenance of the structure and func-
tional life span of the primate corpus luteum [11].
Impairment of corpus luteum function during cycles stimu-
lated with hMG appears to be less with cetrorelix than that
associated with gonadorelin analogues [12,13].
Ganirelix is a potent synthetic third generation GnRH-ant
with only minimal histamine-releasing properties and high
aqueous solubility. The molecule has a ninefold higher
receptor binding affinity (KD ¼ 0:4 nM) as compared to
GnRH (KD ¼ 3:6 nM) [14]. It has been generally well
tolerated in clinical trials.
Degarelix (FE200486) is a member of a new class of long-
acting GnRH-ant. At single SC injections of 0.3–10 mg/kg in
rats, degarelix produced a dose-dependent suppression of
the pituitary–gonadal axis as revealed by the decrease in
plasma LH and testosterone (T) levels. Duration of LH
suppression increased with the dose: in the rat, significant
suppression of LH lasted 1, 2, and 7 days after a single SC
injection of degarelix at 12.5, 50, or 200 mg/kg, respectively.
Degarelix fully suppressed plasma LH and T levels in the
castrated and intact rats as well as in the ovariectomized
(OVX) rhesus monkey for more than 40 days after a single
2 mg/kg SC injection. In comparative experiments, degar-
elix showed a longer duration of action than the GnRH-ant
abarelix, ganirelix, cetrorelix, and azaline B.
The in vivo mechanism of action of degarelix was con-
sistent with competitive antagonism, and the prolonged
action of degarelix was paralleled by continued presence
of radioimmunoassayable degarelix in the general circula-
tion. In contrast to cetrorelix and similarly to ganirelix and
abarelix, degarelix had only weak histamine-releasing prop-
erties in vitro. These results demonstrate that the unique and
favourable pharmacological properties of degarelix make it
an ideal candidate for the management of sex steroid-
dependent pathologies requiring long-term inhibition of
the gonadotropic axis [15].
3. Mechanism of action
The clinical usefulness of the GnRH-a drugs is based on
their ability to reversibly block pituitary gonadotrophin
secretion, thereby preventing a premature surge of LH,
which causes luteinization and disruption of normal follicle
and oocyte development, a situation that was frequently
observed with gonadotrophin-only stimulation protocols.
Recent UK guidelines on infertility management recom-
mend the routine use of gonadorelin analogues in IVF [16].
GnRH plays a crucial role in controlling the ovarian cycle
in women. By modification of the molecular structure of this
decapeptide, analogues were synthesized with agonistic or
antagonistic effects on the gonadotrophic cells of the ante-
rior pituitary gland. The mechanisms of action of GnRH-ant
and of agonists is completely different.
The agonists, after an initial stimulatory effect (flare-up),
lead to desensitisation of the gonadotrophic cells and a
reduction in the number of GnRH-R on the cell membrane
(down-regulation), thereby reducing the release of FSH and
LH, which in turn leads to inhibition of androgen and
oestrogen production, while the antagonists produce an
immediate effect by competitive blockade of the GnRH-R
(Figs. 3–7) [17].
After administration of GnRH-ant, the serum levels of
FSH and LH decrease within hours. Nevertheless, the ade-
nohypophysis maintains its responsiveness to a GnRH sti-
mulus (pituitary response) after pre-treatment with an
antagonist. Due to competitive blockage of GnRH-R by
antagonist administration, LH (and to a lesser extent FSH)
levels drop rapidly. Moreover, pituitary function normalizes
immediately following cessation of medication. This differ-
ent pharmacological mechanism of GnRH-ant makes pos-
sible new approaches to ovarian stimulation and to the
therapy of sex steroid dependent diseases. The direct and
rapid action of GnRH-ant, the dose-dependent suppression
of LH and FSH and the rapid restoration of hypophyseal
function after cessation of the use of antagonists may shorten
and simplify IVF, with less chance of side effects or com-
plications. Antagonists can usefully be applied for other
gynaecological indications such as the polycystic ovarian
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Fig. 3. GnRH analogues: mode of action.
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syndrome (PCOS). The possibilities of profitable long term
treatment will increase considerably if it proves possible to
develop a sustained action formulation [18,19].
4. Pharmacokinetics
GnRH is short-lived with a plasma half-life of 2–5 min
due to rapid enzymatic degradation by peptidases which
interact with peptide in position 6; small amounts of the
unchanged drug (4%) appear in urine.
The pharmacokinetics and pharmacodynamics of GnRH-
ant cetrorelix following single and multiple SC administra-
tion of different doses was investigated in healthy female
volunteers who received either 0.25, 0.50, or 1.00 mg
cetrorelix, in a first menstrual cycle as single-dose and in
a second cycle as multiple-dose (daily between cycle days 3
and 16).
After single administration of each dose, maximum
cetrorelix concentrations (Cmax) were reached after 1 h,
and Cmax and area under the concentration (AUC) time
curve increased linearly with the dose. The median terminal
half-life ranged from 5 to 10 h in the three different dose
groups. FSH, LH, E2, and progesterone (P) concentrations
were suppressed, with a nadir at 6–12 h after cetrorelix
administration.
During multiple administration, Cmax and AUC also
showed dose-linearity. The median terminal half-life of
cetrorelix varied between 20 and 80 h. A dose-dependent
suppression of FSH, LH, and E2 concentrations was
observed during treatment. After multiple administration,
ovulation was delayed for 5, 10, and 13 days in the 0.25,
0.50, and 1.00 mg dose groups, respectively [7].
The bioavailability of cetrorelix after SC injection is
about 85%. It has linear pharmacokinetics, is 85% protein
bound, and has a terminal elimination half-life after SC
administration of about 30 h [5,7].
The development of pharmacokinetic and pharmacody-
namic models for the LH suppression and subsequent shift in
LH surge and FSH by cetrorelix in women was also made in
a placebo-controlled study. Single SC doses of 1, 3, and
5 mg of cetrorelix were given on day 8 of the natural
menstrual cycle. Cetrorelix pharmacokinetics were des-
cribed by a 2-compartment model with a terminal half-life
of 56:9 27:1 h. Mean shift in LH surge was by 4.1, 7.5, and
9.3 days with the 1, 3, and 5 mg doses, respectively. An
indirect response sigmoid Emax model was developed for the
suppression of LH and the shift in the LH surge. The
inhibitory concentration of 50% (for LH suppression) and
median effective concentration (for surge shift) estimates
were 3.6 and 1.6 ng/ml, respectively. The suppression of
FSH was described by a similar Emax model, with an
inhibitory concentration of 50% of 7.25 ng/ml [20].
Regarding ganirelix, the absolute bioavailability after a
single SC injection was assessed in a randomised, crossover,
pharmacokinetic study (phase I clinical research unit).
Healthy female volunteers of reproductive age were sub-
mitted to two separate injections of 0.25 mg of ganirelix, one
SC and one intravenously (IV), with a washout period of 1
week between injections. The mean concentration-time
profile after SC administration was comparable to that after
IV administration. The mean (standard deviation (S.D.))
peak concentration and time of occurrence after SC admin-
istration were 14:8 3:2 and 1:1 0:3 h, respectively. The
mean (S.D.) half-lives after IV administration and SC
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Native molecule excluded from
receptor binding (desensitisation)
Fig. 5. Agonist—chronic administration: suppression.
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administration were highly similar (12:7 3:7 and 12:8
4:3 h, respectively). Mean (S.D.) AUC 0-infinity values of
105 11 and 96 12 ng (ml/h) were calculated for IV
administration and SC administration, respectively, result-
ing in an absolute mean (S.D.) bioavailability of
91:3% 6:7%. Both treatments were well tolerated. In
conclusion, ganirelix is absorbed rapidly and extensively
after SC administration, resulting in a high absolute bioa-
vailability of >90% [21].
The dose-proportionality and pharmacodynamic proper-
ties of multiple-doses of ganirelix were assessed in a ran-
domised, parallel, pharmacokinetic, and pharmacodynamic
study (phase I clinical research unit) on healthy female
volunteers of reproductive age. SC injections of 0.125,
0.25, or 0.50 mg of ganirelix were given once daily for 7
days. Steady-state levels were reached between days 2 and 3.
Peak concentrations, which occurred approximately 1 h
after dosing, increased in a dose-proportional manner and
averaged 5.2, 11.2, and 22.2 ng/ml for the 0.125, 0.25 and
0.50 mg doses, respectively. Corresponding mean values for
the AUC over one dosing interval (24 h) were 33, 77.1, and
137.8 ng (ml/h), respectively. After the last 0.25 mg dose of
ganirelix, serum LH, FSH, and E2 concentrations were
maximally decreased (by 74, 32, and 25% at 4, 16, and
16 h after injection, respectively). Serum hormone levels
returned to pre-treatment values within 2 days after the last
injection. In conclusion, the pharmacokinetics of ganirelix
were dose-proportional within the dose range studied. Multi-
ple injections resulted in immediate suppression of gonado-
trophins, which was rapidly reversed after treatment
discontinuation [22].
5. Indications/contraindications
5.1. Assisted reproduction technologies
One of the first reports on the use of GnRH-ant in
gynaecology is the study by Felberbaum et al. (1995),
who tested the applicability of the GnRH-ant cetrorelix
within COH to avoid the premature LH surge. Patients
suffering from tubal infertility were stimulated for IVF by
hMG and concomitant administration of cetrorelix in dif-
ferent dosages (3, 1 and 0.5 mg). No premature LH surge
could be observed. The authors concluded that short term
administration of the GnRH-ant avoids the occurrence of a
premature LH surge [23].
In a pilot study, to assess the ability of a single injection of
the GnRH-ant cetrorelix to prevent premature LH surges in
an IVF-ET program when administered on a fixed day in the
late follicular phase, these findings were confirmed [24].
The use of GnRH-ant has been studied in ART as part of
the COS procedure in healthy female partners of infertile
couples. The primary endpoint in most studies was preven-
tion of premature LH surge and consequent ovulation in
order to allow the follicles to mature for planned oocyte
collection, although the definition varied between different
study protocols.
Two protocols for ART cycles were designed which were
widely used in COS in several phase II and III studies as well
as in clinical practice since the GnRH-ant cetrorelix and
ganirelix are available on the market: cetrorelix was applied
in single- and multiple-dose protocols; ganirelix was used
until now only according to the multiple-dose protocol. The
single-dose protocol allies simplicity and efficacy, while the
multiple-dose protocol is efficient and could reduce mon-
itoring of the cycle, though compliance is mandatory.An
open-label non randomised clinical study on normal human
volunteers in an academic research center was conducted to
determine if daily SC doses of ganirelix could suppress and
maintain E2  30 pg=ml, the serum profiles of LH and FSH
during and after cessation of treatment, the time-course of
the resumption of normal ovarian function after ganirelix
cessation, and to identify side effects of daily treatment.
Ganirelix treatment rapidly decreased serum levels of gona-
dotrophins and E2 after both 1 and 2 mg administration.
Twenty-four hours after the first dose of ganirelix, E2
decreased from a mean of 50 8 and 67 11 pg=ml at
baseline to 25 4 and 20 3 in the 1 and 2 mg groups,
respectively. E2 remained suppressed (mean levels <26 pg/
ml) on all subsequent 7 days of ganirelix dosing in both
groups. After the final dose of ganirelix, there was a rapid
return of ovarian function in all volunteers. All women had P
levels indicative of ovulation in the subsequent cycle, and
the mean number of days from the final ganirelix dose to the
next menses was 25:8 2:1 and 27:3 1:6 in the 1 and
2 mg groups, respectively. The Authors conclude that daily
ganirelix administration is effective in suppressing the
pituitary–gonadal axis and has a side effect profile that
should be well tolerated [25].
Another pilot study was designed to determine if GnRH-a
could induce a LH surge in patients where a GnRH-ant was
used to prevent premature spontaneous LH surge in women
treated with ovarian stimulation and intrauterine insemina-
tion (IUI) for idiopathic infertility. A LH and FSH surge as
well as a P rise were obtained in the patients studied. A
GnRH-a successfully induced a LH surge after GnRH-ant
administration [26].
In a further study, subtle serum P rise (1.1 ng/ml) during
the late follicular phase was reported for the first time in
patients using cetrorelix, in combination with hMG for
ovarian stimulation prior to intracytoplasmic sperm injec-
tion (ICSI). In 20% of the patients serum P levels were
1.1 ng/ml. The cycle characteristics of the patients were
similar in both groups. No premature endogenous LH surge
occurred and the serum LH concentrations were constantly
low during the follicular phase. The 17-b E2 and FSH
exposure were higher in cycles with premature luteinization.
The greater E2 and FSH exposure confirm that one of
the possible factors inducing subtle serum P rise is the
increased E2- and FSH-induced LH receptivity in granulosa
cells [27].
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The first attempt to treat imminent ovarian hyperstimula-
tion syndrome (OHSS) by using a GnRH-ant was made in
1998 [28]. Moreover, in 1998 a case report described the first
established pregnancy after the use of the GnRH-ant ganir-
elix to prevent a premature LH surge during ovarian hyper-
stimulation with rhFSH. The pregnancy progressed
normally and ended with the birth of a healthy boy and a
girl after an elective caesarean section at gestational age of
37 weeks [29].
Ongoing pregnancies have been also previously achieved
in older recipients with natural cycle oocyte donation from
young donors using a GnRH-ant, with hMG and hCG to
complete oocyte maturation. This provides a new alternative
to ovarian stimulation for both oocyte donation and routine
IVF [30].
GnRH-ant are used also in embryo cryopreservation
programs. Therapeutic regimens for the treatment of malig-
nant disease, in fact, may compromise future fertility. One
approach to circumvent this is the cryopreservation of
embryos created before treatment for the malignancy.
Conventional regimens using GnRH-a are time consum-
ing, requiring pituitary down-regulation before gonadotro-
phin administration, thus the duration of treatment is
approximately 20–30 days. GnRH-ant do not cause an initial
stimulation of gonadotrophin secretion and can thus be
administered during the later stages of follicular maturation
to prevent premature luteinization and ovulation The dura-
tion of ovulation induction/IVF treatment is thus reduced.
These are potential uses and advantages of a GnRH-ant in
ovulation induction/IVF when the need for immediate initia-
tion of treatment and its duration are critical factors [31].
A retrospective data analysis was made to compare the
pregnancy rates of frozen–thawed 2-pronucleate (2PN)
oocytes obtained either in a long protocol or in an antagonist
protocol and ovarian stimulation with either hMG or rhFSH
on infertile couples who underwent a transfer of cryopre-
served 2PN oocytes. Implantation rates in the freeze–thaw
cycles were 5.6% (hMG) and 3.8% (rhFSH) with 2PN
oocytes from the long protocol and 7% from the antagonist
cycles, irrespective of whether hMG or rhFSH was used. PR
were similar independent of whether they resulted from the
long-protocol cycles with hMG (15.4%) and rhFSH (13.1%)
or from the antagonist protocol cycles with hMG (25.0%)
and rhFSH (17.5%). The potential to implant is independent
of the GnRH analogue and gonadotrophin chosen for the
collection cycle when previously cryopreserved 2PN
oocytes were replaced after thawing in the cleavage stage
[32].
IVF patients older than 40 years undergoing IVF-ET
cycles were examined to determine if the use of a mid-cycle
GnRH-ant provided better clinical outcomes and lower
cancellation rates. In the past, COS in women 40 years
was performed with FSH/hMG only and no GnRH-a or -ant
(group I). In subsequent times, following the release of
ganirelix, all women 40 years were stimulated with
FSH/hMG þ ganirelix (group II). Outcomes of IVF cycles
prior to ganirelix were compared to results after its intro-
duction. Cancellation rates were significantly lower in group
II (16%) as compared to group I (67%) (P < 0:05). In
patients with oocytes retrieved, group II had a significantly
higher number of recovered oocytes (7:7 0:8 versus
5:3 0:7, P < 0:05). However, the number of embryos
transferred, cumulative embryo scores, implantation rates
and ongoing PR did not differ significantly between groups.
Although these results were preliminary, the addition of
GnRH-ant avoided ovarian suppression at the start of COH
and prevented the premature LH surge at mid-cycle. Thus,
more patients attempting IVF underwent oocyte retrieval,
although clinical outcomes could not necessarily be
improved [33].
With GnRH-ant, soft stimulation protocols on the basis of
clomiphene pre-treatment should be possible as the pituitary
remains fully sensitive at the beginning of the cycle. A
prospective trial was carried out on patients undergoing IVF
treatment using the multiple-dose GnRH-ant protocol
(cetrorelix), clomiphene citrate (CC), and either hMG or
rhFSH. Both treatment groups, hMG and rhFSH, yielded
comparable results concerning gonadotrophin dose, stimu-
lation days, and PR. A mean number of 6:34 4:4 meta-
phase II oocytes was retrieved and a mean number of
2:45 0:65 embryos was transferred. However, the overall
rate of premature LH surges was 21.5% (defined as mea-
surement of LH > 10 IU/l and P > 1 ng=ml) which is
unacceptable for clinical practice. Increasing the daily
cetrorelix dose from 0.25 to 0.5 mg might decrease the
number of premature LH surges. Soft stimulation protocols
with clomiphene should be used cautiously [34].
Several Authors have suggested that increased plasma
LH levels have deleterious effects on the fertility of
women with PCOS. Indeed, fewer spontaneous pregnan-
cies with more miscarriages are observed when plasma LH
levels are high. ART such as IVF have provided other clues
to the role of the LH secretory pattern in women with
PCOS. The number of oocytes retrieved, the fertilization
rate, and the cleavage rate are lower in PCOS patients
undergoing IVF and this is inversely correlated with FSH/
LH ratio. These abnormalities are corrected when endo-
genous secretion of LH is suppressed. On the other hand,
implantation and PR after IVF are similar to those
observed in control women.
New GnRH-ant are devoid of side effects and suppress LH
secretion within a few hours without a flare-up effect. This
action lasts for 10–100 h. When GnRH-ant are associated
with IV pulsatile GnRH, this combination both suppresses
the effect of endogenous GnRH and because of the competi-
tion for GnRH-R restores a normal frequency of LH secre-
tion.
In conclusion, the combination of GnRH-ant and GnRH
pulsatile treatment can re-establish normal LH secretory
pattern in patients with PCOS. The failure to induce ovula-
tion with this regimen suggests the existence of an inherent
ovarian defect in women with PCOS [35].
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GnRH-ant have been proven safe and effective, with no
adverse effects on offspring in animal studies. Careful study
of pregnancy outcome in humans is mandatory. A prelimin-
ary report includes follow-up data of patients treated with
the GnRH-ant ganirelix during ovarian stimulation for IVF
or ICSI. Patients were randomised in a multicentre, double-
blind, dose-finding study of ganirelix, at six different doses
ranging from 0.0625 to 2 mg. Follow-up of the pregnant
patients revealed 9% of miscarriages. The mean gestational
age was 39.4 weeks for singleton pregnancies, and 36.6
weeks for multiple pregnancies. A birth weight <2500 g was
reported for 8.7 and 54.2% of the infants resulting from
singleton and twins delivery, respectively. One major con-
genital malformation was diagnosed; a boy with Beckwith–
Wiedemann syndrome (exomphalos and macroglossia).
Seven minor malformations were reported among five
infants. In this first follow-up study, the incidence of adverse
obstetrical and neonatal outcome was comparable with
reported incidences for IVF-ET pregnancies [36].
When using GnRH-ant in COS, ovulation or maturation
of the oocyte can be induced by a variety of drugs, e.g. native
GnRH, rhLH, or short-acting GnRH-a. Short-acting GnRH-
a were recommended for triggering ovulation in cases with a
high risk of developing OHSS.
Since it is evident that GnRH is required to initiate the LH
surge and the E2 rise, a single administration of GnRH-ant
during the late follicular phase delays the LH surge. Studies
showed that a single SC administration of 3 or 5 mg of
cetrorelix in the late follicular stage was sufficient to prevent
the LH surge for 617 days. This phenomenon can be used in
high responder patients who are at risk for OHSS. The
question whether this delay has any effect on oocyte quality
and maturation still remains unanswered.
Overall, there are four uses for GnRH-ant:
(1) using short-acting GnRH-a for triggering ovulation in
cases in which the GnRH-ant is part of the protocol for
ovarian stimulation; rhLH and native GnRH could also
be used as triggers of LH surge;
(2) delaying the LH surge in cases of risk to OHSS by
treatment with GnRH-ant;
(3) to administer GnRH-ant during the luteal phase to
decrease the activity of corpora lutea;
(4) in PCOS with elevated LH the LH/FSH ratio can be
corrected with the injection of GnRH-ant prior to and
during ovarian stimulation [37].
Another report described the use of 0.2 mg triptorelin to
trigger ovulation in patients who underwent COH with
rhFSH and concomitant treatment with the GnRH-ant ganir-
elix for the prevention of premature LH surges. All patients
were considered to have an increased risk for developing
OHSS (at least 20 follicles11 mm and/or serum E2 at least
3000 pg/ml). On the day of triggering the LH surge, the
mean number of follicles 11 mm was 25:1 4:5 and the
median serum E2 concentration was 3675 pg/ml (range
2980–7670 pg/ml).
After GnRH-a injection, endogenous serum LH and FSH
surges were observed with median peak values of 219 and
19 IU/l, respectively, measured 4 h after injection. The mean
number of oocytes obtained was 23:4 15:4, of which 83%
were mature (metaphase II). None of the patients developed
any signs or symptoms of OHSS. So far, four clinical
pregnancies have been achieved from the embryos obtained
during these cycles, including the first birth following this
approach. It is concluded that GnRH-a effectively triggers an
endogenous LH surge for final oocyte maturation after
ganirelix treatment in stimulated cycles. These preliminary
results suggest that this regimen may prove effective in
triggering ovulation and could be said to prevent OHSS
in high responders [38].
The use of cetrorelix in conjunction with CC and gona-
dotrophin has been assessed in IVF/gamete intra-fallopian
transfer (GIFT) cycles for poor responders. Group I
included difficult responders (24 cycles) with no live birth
in previous IVF cycles with GnRH-a. Group II included
patients (7 cycles) with polycystic ovaries. The treatment
protocol involved a daily dose of CC 100 mg for 5 days and
gonadotrophin injections from cycle day 2. Cetrorelix
0.25 mg per day was started when the leading follicle
reached 14 mm. The outcome in both groups was favourable
compared to previous treatment with GnRH-a. In group I the
abandoned cycle rate was 29% versus 57% (P ¼ 0:06).
More oocytes were produced (6.4 versus 4.7 oocytes/cycle)
at a lower dose of FSH (709 versus 1163 IU/oocyte;
P ¼ 0:08) and two live births resulted (11.8%). In group
II fewer oocytes were produced (10.2 versus 14.5 oocytes/
cycle), using a lower dose of gonadotrophin (170 versus 189
IU/oocyte) and resulted in one ongoing pregnancy. No
patients experienced OHSS [39].
Patients with a poor response in previous treatment
cycles were included in another study. They were divided
into two groups: group I received ovarian stimulation for
20 cycles, without the addition of either GnRH-a or -ant;
while group II patients received ovarian stimulation for 20
cycles, including the administration of a GnRH-ant
(cetrorelix, 0.25 mg daily) during the late follicular phase.
There was no statistically significant difference between
the groups for mean age, duration of infertility, baseline
FSH concentration, cancellation rate, number of ampoules
of gonadotrophin used, number of mature oocytes
retrieved, E2 concentrations on the day of injection of
hCG, fertilization rate, and number of embryos trans-
ferred. The clinical pregnancy and implantation rates in
group II appeared higher than in group I, but were not
significantly different (20 and 13.33% compared with 6.25
and 3.44%, respectively) [40].
5.2. Other indications
For male hormonal contraception, combined administra-
tion of GnRH-ant and androgens effectively suppresses
spermatogenesis to azoospermia [41].
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Treatment with GnRH-a of uterine myoma, endometrio-
sis, and some hormone-dependent cancers, such as breast,
ovarian, endometrial, and prostate cancer, seems to have a
beneficial effect. The use of GnRH-ant, which cause an
immediate and dose-related inhibition of LH and FSH by
competitive blockade of the receptors, is much more advan-
tageous. Clinical trials in patients are currently in progress
and have already shown the usefulness of this new treatment
modality [42,43].
5.3. Contraindications
GnRH-ant are contra-indicated in pregnancy and lacta-
tion, postmenopausal women, patients with moderate to
severe renal or hepatic impairment, and those with hyper-
sensitivity to these drugs, extrinsic peptide hormones, or
mannitol. To date no clinically significant drug interactions
have been documented.
6. Dosage and administration
The peptide agonists and antagonists currently available
require parenteral administration, typically in the form of
long-acting depots. A new generation of non-peptide GnRH-
ant are beginning to emerge which should allow oral admin-
istration and, therefore, may provide greater flexibility of
dosing, lower costs and increased patient acceptance [44].
Two different protocols have been investigated (Figs. 8
and 9):
(1) in multiple-doses regimen (the Lubeck protocol), small
doses of antagonist (0.25 mg once daily by SC
injection into the lower abdominal wall) are injected
in the morning, starting on day 5 or 6 of ovarian
stimulation with gonadotrophins (or each evening
starting on day 5 of ovarian stimulation) and continue
throughout gonadotrophin treatment, including day of
ovulation induction (or evening before ovulation
induction) with hCG;
(2) in the single-dose regimen (the French protocol), one
injection of a larger dose (3 mg by SC injection into the
lower abdominal wall) is proposed in the late follicular
phase on day 7 of ovarian stimulation with gonado-
trophins. If follicle growth does not allow ovulation
induction on the 5th day after injection, an additional
dose of 0.25 mg once daily until the day of ovulation
induction is suggested.
The remaining levels of endogenous LH appear to be
sufficient in the multiple-doses protocol. In the single an
E2 drop is observed in some patient following the 3 mg
injection of cetrorelix. This drop is related to the LH
decrease. Its adverse effect on IVF results is not demon-
strated [45].
7. Advantages/adverse effects
7.1. Advantages
The use of GnRH-ant offers several potential advantages
over gonadorelin analogues. Instead of down-regulation and
desensitisation, the GnRH-R on the cell membrane are
blocked. There is no initial stimulation (flare-up), the treat-
ment period can be shorter, and there is a suggestion that
lower doses of gonadotrophins may be required [5,18]. The
main advantages for women treated with cetrorelix are the
avoidance of hormonal withdrawal side effects (e.g. hot
flushes) and the convenience of the dosage regimen includ-
ing the fact that:
 no pre-treatment is required before gonadotrophin usage;
 results of clinical trials to date suggest that with GnRH-
ant much shorter treatment regimens;
 with fewer injections and possibly less gonadotrophin can
achieve good clinical results [46];
 fertilization rates of >60% as well as clinical PR of about
30% per transfer sound most promising;
 E2 secretion is not compromised by the GnRH-ant using
rhFSH for COH;
 the incidence of a premature LH surge is far below 2%
while the pituitary response remains preserved, allowing
the induction of ovulation by GnRH or GnRH-a [47,48];
 cetrorelix is being promoted on the basis that it eliminates
the need for long term down-regulation, fits into the
natural menstrual cycle, reduces the risk of OHSS, and
avoids hormonal withdrawal symptoms. These claims can
be supported by published data.
Cetrorelix is more expensive than agonists used in COS
although there may be some economic benefit in terms of
fewer clinic attendances and time off work for the patient.
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Gonadotrophins
Cetrorelix
(3 mg, 1 mg, 0.5mg,0.25 mg/day)
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menses
4
3 
2 
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Fig. 8. The ‘‘Lubeck Protocol’’.
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3 mg SC
hCG OPU ET
Fig. 9. The ‘‘French Protocol’’.
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More data are needed before its relative cost-effectiveness
can be determined.
7.2. Adverse effects
The most common adverse events are mild transient local
injection site reactions, e.g. erythema, itching, and swelling,
which may occur. Occasionally asthenia, nausea, malaise,
headache, and fatigue have been reported [5,49].
A prospective, randomised phase III clinical trial was
conducted to study the influence of an GnRH-ant protocol
(cetrorelix) and the use of rhFSH on the development of
leukocytosis, compared to the use of urinary hMG (uhMG)
on patients undergoing IVF/ICSI treatment following COS
using a multiple-dose protocol and the GnRH-ant cetrorelix.
Statistically significant increase in white blood cell (WBC)
count in the hMG group from the start of stimulation to the
mid-luteal phase were detected. No statistically significant
increase in the rhFSH group, but only a trend towards higher
values was observed. The development of a leukocytosis in
COS did not depend on the protocol used [50].
There is a wide variety of functional and morphological
effects of GnRH analogues on the ovary. The sometimes
paradoxical effects indicate that a variety of factors may be
involved in the various processes. Those factors are:
 the type and dose of the analogue;
 the different regimens of administration;
 ovarian status at the time of exposure;
 ovarian cell types in in vitro systems;
 hormonal pre-treatment of these cultures;
 the type of hormonal stimulation added to the in vitro
culture;
 further methodological differences in the experiments;
 physiological variations in GnRH-R abundance which
depends on species and/or timing in the cycle.
With the increasing number of patients using GnRH
analogues in ART, there will be an increasing number of
pregnancies exposed to these drugs. So far, there does not
appear to be an increased risk of birth defects or pregnancy
wastage in human pregnancies exposed to daily low-dose
GnRH-a therapy in the first weeks of gestation [51].
8. Efficacy
Open studies in more than 100 women confirmed that
cetrorelix as a single-dose (3 or 5 mg) or in a range of
multiple-doses significantly suppressed LH and prevented
the LH surge [24,52–55]. Two non-randomised dose finding
studies evaluated the minimal effective single-dose of
cetrorelix and the efficacy of multiple-doses. Cetrorelix
3 mg was compared with 2 mg in women undergoing
IVF. Treatment was administered on day 8 of cycle. There
was one LH surge and LH was suppressed for a shorter time
in the 2 mg group. IVF results were comparable [56]. In
another comparison of cetrorelix 0.1, 0.25, or 0.5 mg daily in
the multiple-dose regimen, the minimal effective dose was
found to be 0.25 mg daily [57].
A multicentre, double-blind, randomised dose-finding
study of Org 37462 (ganirelix) was conducted in women
undergoing ovarian stimulation with rhFSH to establish the
minimal effective dose preventing premature LH surges
during ovarian stimulation. Serum Org 37462 concentra-
tions increased in a linear dose-proportional manner,
whereas serum LH and increases of E2 fell with increasing
Org 37462 dose. During Org 37462 treatment, serum LH
concentrations 10 IU/l were observed in the lowest dose
groups with incidences of 16% (0.0625 mg), 9% (0.125 mg),
and 1.4% (0.25 mg). On the day of hCG, the number of
follicles11,15, and17 mm were similar in the six dose
groups, whereas serum E2 concentrations were highest in
the 0.0625 mg group (1475 pg/ml) and lowest in the 2 mg
group (430 pg/ml).
The median daily dose of rhFSH was between 150 and
183 IU and the overall median duration of Org 37462
treatment was approximately 5 days in the six treatment
groups. Overall, Org 37462 treatment appeared to be safe
and well tolerated. The mean number of recovered oocytes
and good-quality embryos was similar in all dose groups and
ranged from 8.6 to 10.0 and 2.5–3.8, respectively. The mean
number of replaced embryos in the different dose groups
ranged from 2.3 to 2.7. The implantation rate was highest in
the 0.25 mg group (21.9%) and lowest in the 2 mg group
(1.5%). The early miscarriage rates (first 6 weeks after ET)
were 11.9 and 13% in the 1 and 2 mg group, respectively,
whereas in the other dose groups this incidence was zero
(0.0625%) up to a maximum of 3.7% (0.5 mg group). The
vital PR (with heart activity) at 5–6 weeks after ET was
highest in the 0.25 mg group, i.e. 36.8% per attempt and
40.3% per transfer, and resulted in an ongoing PR 12–16
weeks after ET of 33.8% per attempt and 37.1% per transfer.
In conclusion, a daily dose of 0.25 mg Org 37462 prevented
LH surges during ovarian stimulation and resulted in a good
clinical outcome [58].
In another trial, a significant drop in plasma LH concen-
tration was observed within a few hours of the first admin-
istration of GnRH-ant (cetrorelix) (P < 0:005). Moreover,
no LH surge was detected at any point in the treatment
period in any of the patients. A mean E2 concentration of
2111 935 ng=l was observed on the day of the hCG
administration, indicating normal folliculogenesis. Like
LH, P concentration also dropped within a few hours of
the first administration of cetrorelix (P < 0:005) [53].
A study was performed to evaluate the effect of GnRH-ant
(Nal-Glu) administration in women after the beginning of
the LH surge. Twenty-four hours after administration of the
antagonist, the LH surge had been interrupted in all subjects.
LH levels fell by 68.5%, E2 by 42%, and FSH by 53.2%
[59].
Several studies have directly compared these new stimu-
lation protocols against the long GnRH-a protocol.
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A multi-centre phase III randomised study compared
cetrorelix and buserelin in the prevention of LH surge during
ovarian stimulation in IVF/ICSI cycles. The intention to
treat response rate, defined as the number of women reach-
ing hCG injection day in the absence of LH surge, was
96.3% for cetrorelix and 90.6% for buserelin. In the cetror-
elix group significantly fewer hMG ampoules were admi-
nistered and the mean number of hMG stimulation days was
significantly less (P < 0:01). The incidence of premature
luteinization with cetrorelix was 1.6%. On the day of hCG
administration, more follicles of a small diameter were
observed with buserelin (P ¼ 0:02) and the mean serum
E2 concentration was significantly higher with buserelin
(P < 0:01). Fertilization and PR were similar in the two
groups. The mean number of treatment days was 5.7 days for
cetrorelix and 26.6 days for buserelin. The incidence of
OHSS World Health Organization (WHO) grades II and III
was significantly higher with buserelin (6.5% versus 1.1%,
P ¼ 0:03) [60].
Another multicenter randomised, prospective study was
conducted to confirm the value of a single-dose of 3 mg of
cetrorelix versus triptorelin depot in preventing the occur-
rence of premature LH surges. No LH surge occurred after
cetrorelix administration. The patients in the cetrorelix
group had a lower number of oocytes and embryos. The
percentage of mature oocytes and fertilization rates were
similar in both groups, and the PR were not statistically
different. The length of stimulation, number of hMG
ampoules administered, and occurrence of the OHSS were
lower in the cetrorelix group. Tolerance of cetrorelix was
excellent [61].
A prospective, randomised study was performed to com-
pare the efficiency of hormonal stimulation for IVF in either
the long luteal protocol, using the GnRH-a buserelin, or the
multiple-dose GnRH-ant protocol, using the GnRH-ant
cetrorelix. The incidence of WHO grade II and grade III
OHSS was significantly lower in the cetrorelix than in the
buserelin group (1.1% versus 6.5%, P ¼ 0:03). The follicle
maturation was more homogeneous in the cetrorelix proto-
col, with less small follicles on the day of hCG adminis-
tration but a similar number of oocyte cumulus complexes
retrieved. The PR per cycle were not significantly different
in the cetrorelix and buserelin protocol (22% versus 26%).
So, the cetrorelix multiple-dose protocol is advantageous
compared to the long protocol regarding the incidence of
OHSS, a potentially life threatening complication of COS
[62].
A meta-analysis was performed to evaluate whether there
is a reduction in cases of OHSS and/or a reduction in PR.
There was a significant reduction of OHSS cases in the
cetrorelix studies (odds ratio, OR, 0.23; 95% confidence
interval, CI, 0.10–0.54), but no reduction for ganirelix (OR
1.13; 95% CI 0.24–5.31). The incidence of OHSS WHO
grade III cases was reduced in the cetrorelix protocols as
compared to the long protocol to a nearly significant degree
(OR 0.26; 95% CI 0.07–1.01), while ganirelix did not reduce
the incidence of OHSS WHO grade III at all (OR 1.08; 95%
CI 0.27–4.38). The PR per cycle was significantly lower in
the ganirelix protocols than in the long protocol (OR 0.76;
95% CI 0.59–0.98). The studies using cetrorelix showed
quite similar, not significantly different results for the
antagonist and the long protocol groups for the PR per cycle
(OR 0.91; 95% CI 0.68–1.22). From the data one can
conclude that cetrorelix but not ganirelix will reduce the
incidence of cases of OHSS and that cetrorelix but not
ganirelix will result in the same PR as the long protocol [63].
Randomised controlled studies comparing different pro-
tocols of GnRH-ant with GnRH-a in assisted conception
cycles were included in a Cochrane review. In comparison to
the long protocol of GnRH-a, the overall OR for the pre-
vention of premature LH surges was 1.76 (95% CI 0.75,
4.16), which is not statistically significant. There were
significantly fewer clinical pregnancies in those treated with
GnRH-ant (OR 0.78, 95% CI 0.62, 0.97). The absolute
treatment effect (ATE) was calculated to be 5%. The number
needed to treat (NNT) was 20. There was a statistically
significant reduction in incidence of severe OHSS (relative
risk, RR, 0.36, 95% CI 0.16, 0.80) using antagonist regimens
as compared to the long GnRH-a protocol.
The reviewer’s conclusions were the following:
 the new fixed GnRH-ant protocol (i.e. with antagonist
start fixed on day 6 of gonadotrophin-stimulation) is a
short and simple protocol with a significant reduction in
incidence of severe OHSS but a lower PR compared to the
GnRH-a long protocol;
 there is a non significant difference between both proto-
cols regarding prevention of premature LH surge;
 the clinical outcome may be further improved by devel-
oping more flexible antagonist regimens taking into
account individual patient characteristics; the GnRH-
ant flexible regimen should be the area of research in
the near future [64,65].
8.1. Implications
GnRH-ant’s fixed protocol facilitates short and simple
protocol for ovarian stimulation in assisted conception.
However, in view of the available data, the GnRH-ant
regimens have been associated with a slightly lower preg-
nancy and implantation rate than the established GnRH-a
protocols. This remains the biggest hurdle to their more
general acceptance. Differences in serum E2 patterns pre-
ceding oocyte retrieval are the most likely contributing
factor [47]. So, counseling subfertile couples necessitates
before recommending change from GnRH-a to -ant. Cost
effectiveness analysis should be carried out to evaluate the
difference between the two protocols regarding cost per
pregnancy.
The use of a fixed protocol that starts GnRH administra-
tion on a fixed day of the cycle with a fixed dose should be re-
evaluated because it causes planning problems within the
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centres. To overcome some use programming cycle with oral
contraceptives but it has an immediate negative effect on the
duration of the treatment. Impact of GnRH-ant on the
endometrium and subsequent implantation potential should
be examined. Other limits are related to the following
issues.
 Multicentre trials have significant difference between
centres.
 Variation on starting dose.
 Optimal antagonist treatment has not been established.
The future research should focus on:
 safety aspect on ovary-oocytes granulosa cells and
embryo;
 lower implantation rate with higher dose of ganirelix
which is possibly related to:
 direct effect on embryos;
 endometrium.
9. Conclusions
GnRH analogues have made possible new approaches to
the treatment of some hormone-dependent cancers and
diseases and conditions which result from inappropriate
sex hormone levels. In the fields of both gynaecology and
oncology, the development of sustained delivery depot
systems has played a key role in the clinical use of
GnRH-a and is also essential for the GnRH-ant.
GnRH-a have been employed in IVF-ET programs to
prevent a premature rise in LH and various results suggest
that the use of antagonist cetrorelix in assisted reproduction
procedures, could be even more advantageous.
Two protocols for ART cycles were designed: the Lubeck
protocol (single-dose) allies simplicity and efficacy, while
the French protocol (multiple-dose) is efficient and could
reduce monitoring of the cycle, though compliance is man-
datory. Both protocols using GnRH-ant were associated with
the need for a smaller dose of gonadotrophin, a shorter
stimulation period and a lower incidence of OHSS, albeit
with statistically comparable PR. A trend is observed in all
studies showing a lower PR in GnRH-ant cycles as com-
pared with GnRH-a cycles. The role of the lower number of
embryos, and the potential adverse effects of GnRH-ant on
endometrium or follicle must be studied. More cycles using
GnRH-ant are necessary to confirm their equivalent PR.
There is room for improvement in both protocols with regard
to scheduling, antagonist dose level and the timing of its
administration.
Until further studies have been conducted, luteal support
seems to remain mandatory. Perinatal outcome appears
similar to that with other stimulation regimens. Triggering
of ovulation can be obtained with GnRH-a for patients at risk
of OHSS. With regard to GnRH-ant, questions remain
regarding PR, the indications of their use in patients with
PCOS or poor responders, and in ovarian stimulation outside
IVF [66,67].
10. Condensation
This article represents an extensive review of all actual
GnRH-antagonist applications.
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